Records containing: Multiple Myeloma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-11-12Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-11-12A Phase 2, Multicenter, Open Label, Non-randomized Study to Evaluate the Efficacy and Safety of Extended Dosing of Belantamab Mafodotin in Different Combinations With Standard of Care Regimens in Participants With Relapsed-refractory Multiple Myeloma (DREAMM-15)
-
CLINICAL_TRIALS study record update · 2025-11-10Sleep Apnea in Patients With MGUS and MM
-
CLINICAL_TRIALS study record update · 2025-11-10ClinicalTrials.gov study NCT05164250
-
CLINICAL_TRIALS study record update · 2025-11-10Long-term Follow-up Study of Patients Receiving CAR-T Cells
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-11-06A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
-
CLINICAL_TRIALS study record update · 2025-11-04Phase II Study of Interleukin 6 Blockade With Siltuximab to Decrease Symptom Burden in Patients Age 60-75 Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma and AL Amyloidosis
-
CLINICAL_TRIALS study record update · 2025-11-04A Phase Ib Study Of The Combination Of CD47 Blockade With SIRP-Alpha FC Fusion Proteins (TTI-622) And Daratumumab Hyaluronidase-fihj For Patients With Relapsed or Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-10-30Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-10-30A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity Conditioning
-
CLINICAL_TRIALS study record update · 2025-10-27IIT2023-03-Vescio-ColdCap: Scalp Cooling to Prevent Hair Loss in Patients Undergoing Stem Cell Transplantation for Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-10-22A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-10-21A Phase 2 Study of Colesevelam for Lenalidomide-Associated Diarrhea
-
CLINICAL_TRIALS study record update · 2025-10-21High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
-
CLINICAL_TRIALS study record update · 2025-10-20A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-10-20Study of Isatuximab Plus Pomalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Relapsed or Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-10-15A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5- Sub-study 5 - Belantamab Mafodotin and Isatuximab in Combination
-
CLINICAL_TRIALS study record update · 2025-10-15A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 2 - Belantamab Mafodotin and Feladilimab (GSK3359609) in Combination
-
CLINICAL_TRIALS study record update · 2025-10-15Phase I Study of Escalating-Doses of Bendamustine for Patients With Previously Treated Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-10-14Genetic Epidemiology of Lymphoproliferative Disorders
-
CLINICAL_TRIALS study record update · 2025-10-10Pharmacokinetic (PK)-Directed Dosing of Captisol Enabled Melphalan for Patients With Multiple Myeloma or Light Chain (AL) Amyloidosis Undergoing High Dose Therapy and Autologous Hematopoietic Progenitor Cell Transplant
-
CLINICAL_TRIALS study record update · 2025-10-10Umbilical Cord Blood Transplantation From Unrelated Donors
-
CLINICAL_TRIALS study record update · 2025-10-07A Phase 2, Randomized, Parallel, Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-agent Belantamab Mafodotin (GSK2857916) in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM-14)
-
CLINICAL_TRIALS study record update · 2025-10-07A Phase II Study of Daratumumab With Weekly Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-10-07Elranatamab, Lenalidomide, Dexamethasone in Newly Diagnosed Multiple Myeloma, a Clinical and Correlative Phase 2 Study